Johnson & Johnson Eyes Protagonist: A Biotech Acquisition?
Update: 2025-10-10
Description
Johnson & Johnson eyes Protagonist Therapeutics in a potential $4.2 billion deal, fueled by their collaboration on the groundbreaking oral immune disease treatment, icotrokinra. Will this acquisition reshape the market and accelerate access to vital therapies, or will the silence from both companies continue? Find out why investors are buzzing and what this could mean for the future of medical breakthroughs.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
